Skip to nav Skip to content
Mauricio  Silva Almeida Ribeiro

Mauricio Silva Almeida Ribeiro, MD

4.9 (44)

Specialty: Medical Oncology

Program: Sarcoma

Language(s): English

  • Overview

    Cancer Focus:
    GIST (Gastrointestinal Stromal Tumor), Osteosarcoma, Sarcoma

    Dr. Ribeiro is a Medical Oncologist and Assistant Member at the Sarcoma Department. He received his MD degree and completed an Internal Medicine residency at the Sao Paulo State University in Botucatu/Sao Paulo, Brazil. He then completed a Medical Oncology fellowship at Hospital Sírio-Libanês, in São Paulo, where he continued working as a Medical Oncologist until he moved to Canada in 2021.Subsequently, Dr. Ribeiro completed a Clinical Research Fellowship in Sarcoma/Cutaneous Oncology at the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, University of Toronto, Canada. Dr. Ribeiro’s clinical interest focus on providing care to adult soft-tissue sarcoma patients, mostly those diagnosed with liposarcoma, leiomyosarcoma, GIST, vascular sarcomas and desmoid-type fibromatosis. He is particularly interested radiation-associated sarcomas, GIST, ultra-rare sarcomas, desmoid-type fibromatosis, clinical and database research. He is member of the following professional societies: American Society of Clinical Oncology, European Society of Medical Oncology, Connective Tissue Oncology Society, Transatlantic Australasian Retroperitoneal Sarcoma Working Group, and the Brazilian Society of Clinical Oncology.   

  • Publications

    • Ribeiro MF, Demicco EG, Razak ARA. Clinical activity of pembrolizumab in refractory MDM2-amplified advanced intimal sarcomas. Ther Adv Med Oncol. 2024 May.16. Pubmedid: 38745586. Pmcid: PMC11092541.
    • Ribeiro MF, Peretz Soroka H, Bhura Z, Hirsch I, Wunder J, Ferguson P, Tsoi K, Brar S, Gladdy R, Swallow C, Chung P, Catton C, Wong P, Watson G, Razak ARA, Gupta AA, Shultz D. Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study. Ther Adv Med Oncol. 2023 Sep.15. Pubmedid: 37781501. Pmcid: PMC10540571.
    • Queiroz MM, Sacardo KP, Ribeiro MF, Gadotti LL, Saddi R, Oliveira LJC, Linck RDM, Cruz MRS, Barroso-Sousa R, Sahade M, Correa TS, Mano MS, Suzuki DA, Shimada AK, Katz A. Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil. Cancer Treat Res Commun. 2023 May.35:100683. Pubmedid: 36716534.
    • Dutra MP, Rodrigues CM, Peretz-Soroka H, Ribeiro M, Shultz D, Hodgson D, Tsang DS, Gupta AA. Radiation-induced sarcomas following childhood cancer - A Canadian Sarcoma Research and Clinical Collaboration Study (CanSaRCC). Cancer Rep (Hoboken). 2023 Jun.6(6):e1834. Pubmedid: 37178052. Pmcid: PMC10242652.
    • Kibel S, Kuehne N, Ribeiro MF, Muniz TP, Ye XY, Spreafico A, Saibil SD, Sun A, Mak DY, Gray D, Jones B, Wong P, Butler MO. The Role of Adjuvant Radiotherapy for the Treatment of Resected High-Risk Stage III Cutaneous Melanoma in the Era of Modern Systemic Therapies. Cancers (Basel). 2023 Dec.15(24). Pubmedid: 38136412. Pmcid: PMC10741555.
    • Jablonska PA, Muniz T, Ribeiro M, Liu ZA, Ye XY, Devaraja K, Laperriere N, Millar BA, Conrad T, Kongkham P, Butler M, Shultz DB. Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis. J Neurooncol. 2023 Aug.164(1):199-209. Pubmedid: 37552363.
    • Koch Hein EC, Vilbert M, Hirsch I, Fernando Ribeiro M, Muniz TP, Fournier C, Abdulalem K, Saldanha EF, Martinez E, Spreafico A, Hogg DH, Butler MO, Saibil SD. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre. Cancers (Basel). 2023 Aug.15(17). Pubmedid: 37686588. Pmcid: PMC10487051.
    • Kobayashi Y, Oxnard GR, Cohen EF, Mahadevan NR, Alessi JV, Hung YP, Bertram AA, Heppner DE, Ribeiro MF, Sacardo KP, Saddi R, Macedo MP, Blasco RB, Li J, Kurppa KJ, Nguyen T, Voligny E, Ananda G, Chiarle R, Katz A, Tolstorukov MY, Sholl LM, Jänne PA. Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nat Commun. 2022 Sep.13(1):5614. Pubmedid: 36153311. Pmcid: PMC9509394.
    • Ribeiro MFSA, Gadotti LL, Sacardo KP, Lopes CDH, Saddi R, Alessi JVM, de Macedo MP, do Nascimento ECT, Testagrossa LA, Katz A. Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma. SAGE Open Med Case Rep. 2022 May.10. Pubmedid: 35619747. Pmcid: PMC9127844.
    • Gadotti LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, Saddi R, Machado Alessi JV, de Abreu Testagrossa L, Katz A. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma. Clin Lung Cancer. 2021 May.22(3):e481-e486. Pubmedid: 32771343.
    • Sandoval RL, Masotti C, de Macedo MP, Ribeiro MFSA, Leite ACR, Meireles SI, Bovolin RM, Santini FC, Munhoz RR, Jardim DLF, Katz A, Camargo AA, Fernandes GDS, Achatz MI. Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. JCO Glob Oncol. 2021 Jul.7:1141-1150. Pubmedid: 34270331. Pmcid: PMC8457781.
    • Ribeiro MFSA, Knebel FH, Bettoni F, Saddi R, Sacardo KP, Canedo FSNA, Alessi JVM, Shimada AK, Marin JFG, Camargo AA, Katz A. Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient. NPJ Precis Oncol. 2021 Feb.5(1):5. Pubmedid: 33580193. Pmcid: PMC7880994.
    • Ribeiro MFSA, Alessi JVM, Oliveira LJC, Gongora ABL, Sacardo KP, Zucchetti BM, Shimada AK, de Galiza Barbosa F, Feher O, Katz A. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series. Lung Cancer. 2020 Jan.139:9-12. Pubmedid: 31698333.
    • Knebel FH, Barber LJ, Newey A, Kleftogiannis D, Woolston A, Griffiths B, Fenwick K, Bettoni F, Ribeiro MFSA, da Fonseca L, Costa F, Capareli FC, Hoff PM, Sabbaga J, Camargo AA, Gerlinger M. Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. Cancers (Basel). 2020 Dec.12(12). Pubmedid: 33322618. Pmcid: PMC7764102.
    • Vieira AC, Ribeiro MFSA, Lima J, Filho JS, de Andrade Carvalho H, Mano MS. Takotsubo syndrome induced by brachytherapy in a patient with endocervical adenocarcinoma. Cardiooncology. 2020 Dec.6(1):30. Pubmedid: 33292719. Pmcid: PMC7718687.
    • Ribeiro MFSA, de Sousa MC, Hanna SA, Maldaun MVC, Kurimori CO, de Lima LGCA, Mattedi RL, Munhoz RR. Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma. Case Rep Oncol Med. 2018 Apr.2018:4290131. Pubmedid: 29850323. Pmcid: PMC5914121.
  • Patient Comments

    Overall Satisfaction


    44 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor